Article
L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin.
The Journal of biological chemistry - 7 Oct 2011
Osawa Yosuke, Kanamori Hiromitsu, Seki Ekihiro, Hoshi Masato, Ohtaki Hirofumi, Yasuda Yoichi, Ito Hiroyasu, Suetsugu Atsushi, Nagaki Masahito, Moriwaki Hisataka, Saito Kuniaki, Seishima Mitsuru
Abstract excerpt
Nonalcoholic fatty liver disease is one of the most common liver diseases. L-tryptophan and its metabolite serotonin are involved in hepatic lipid metabolism and inflammation. However, it is unclear whether L-tryptophan promotes hepatic steatosis. To explore this issue, we examined the role of L-tryptophan in mouse hepatic steatosis by using a high fat and high fructose diet (HFHFD) model. L-tryptophan treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
